- Home
- EDTK vs NERV Comparison
EDTK vs NERV Comparison
Compare EDTK & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- NERV
- Stock Information
- Founded
- EDTK 2013
- NERV 2007
- Country
- EDTK China
- NERV United States
- Employees
- EDTK 28
- NERV N/A
- Industry
- EDTK Other Consumer Services
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- NERV Health Care
- Exchange
- EDTK Nasdaq
- NERV Nasdaq
- Market Cap
- EDTK 17.7M
- NERV 14.6M
- IPO Year
- EDTK 2020
- NERV 2014
- Fundamental
- Price
- EDTK $1.06
- NERV $2.18
- Analyst Decision
- EDTK
- NERV Hold
- Analyst Count
- EDTK 0
- NERV 1
- Target Price
- EDTK N/A
- NERV $5.00
- AVG Volume (30 Days)
- EDTK 11.0K
- NERV 16.8K
- Earning Date
- EDTK 08-08-2025
- NERV 11-04-2025
- Dividend Yield
- EDTK N/A
- NERV N/A
- EPS Growth
- EDTK N/A
- NERV N/A
- EPS
- EDTK N/A
- NERV 1.48
- Revenue
- EDTK $893,690.00
- NERV N/A
- Revenue This Year
- EDTK N/A
- NERV N/A
- Revenue Next Year
- EDTK N/A
- NERV N/A
- P/E Ratio
- EDTK N/A
- NERV $1.42
- Revenue Growth
- EDTK N/A
- NERV N/A
- 52 Week Low
- EDTK $0.80
- NERV $1.15
- 52 Week High
- EDTK $1.20
- NERV $2.83
- Technical
- Relative Strength Index (RSI)
- EDTK 48.86
- NERV 52.97
- Support Level
- EDTK $1.07
- NERV $2.06
- Resistance Level
- EDTK $1.14
- NERV $2.15
- Average True Range (ATR)
- EDTK 0.04
- NERV 0.12
- MACD
- EDTK -0.00
- NERV -0.01
- Stochastic Oscillator
- EDTK 20.00
- NERV 50.00
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.